180 related articles for article (PubMed ID: 19843689)
1. Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.
Kekatpure VD; Boyle JO; Zhou XK; Duffield-Lillico AJ; Gross ND; Lee NY; Subbaramaiah K; Morrow JD; Milne G; Lippman SM; Dannenberg AJ
Cancer Prev Res (Phila); 2009 Nov; 2(11):957-65. PubMed ID: 19843689
[TBL] [Abstract][Full Text] [Related]
2. Elevated Levels of Urinary PGE-M Are Found in Tobacco Users and Indicate a Poor Prognosis for Oral Squamous Cell Carcinoma Patients.
Kekatpure VD; Bs N; Wang H; Zhou XK; Kandasamy C; Sunny SP; Suresh A; Milne GL; Kuriakose MA; Dannenberg AJ
Cancer Prev Res (Phila); 2016 Jun; 9(6):428-36. PubMed ID: 27045033
[TBL] [Abstract][Full Text] [Related]
3. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers.
Gross ND; Boyle JO; Morrow JD; Williams MK; Moskowitz CS; Subbaramaiah K; Dannenberg AJ; Duffield-Lillico AJ
Clin Cancer Res; 2005 Aug; 11(16):6087-93. PubMed ID: 16115954
[TBL] [Abstract][Full Text] [Related]
4. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Mohebati A; Milne GL; Zhou XK; Duffield-Lillico AJ; Boyle JO; Knutson A; Bosworth BP; Kingsley PJ; Marnett LJ; Brown PH; Akpa EG; Szabo E; Dannenberg AJ
Cancer Prev Res (Phila); 2013 Jul; 6(7):646-55. PubMed ID: 23682075
[TBL] [Abstract][Full Text] [Related]
5. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.
Duffield-Lillico AJ; Boyle JO; Zhou XK; Ghosh A; Butala GS; Subbaramaiah K; Newman RA; Morrow JD; Milne GL; Dannenberg AJ
Cancer Prev Res (Phila); 2009 Apr; 2(4):322-9. PubMed ID: 19336727
[TBL] [Abstract][Full Text] [Related]
6. Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study.
Dong LM; Shu XO; Gao YT; Milne G; Ji BT; Yang G; Li HL; Rothman N; Zheng W; Chow WH; Abnet CC
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3075-8. PubMed ID: 19861525
[TBL] [Abstract][Full Text] [Related]
7. Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Su YY; Chien CY; Luo SD; Huang TL; Lin WC; Fang FM; Chiu TJ; Chen YH; Lai CC; Hsu CM; Li SH
World J Surg Oncol; 2016 Mar; 14():86. PubMed ID: 27001663
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E(2) pathway in head and neck squamous cell carcinoma.
Camacho M; León X; Fernández-Figueras MT; Quer M; Vila L
Head Neck; 2008 Sep; 30(9):1175-81. PubMed ID: 18642283
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.
Edelman MJ; Tan MT; Fidler MJ; Sanborn RE; Otterson G; Sequist LV; Evans TL; Schneider BJ; Keresztes R; Rogers JS; de Mayolo JA; Feliciano J; Yang Y; Medeiros M; Zaknoen SL
J Clin Oncol; 2015 Jan; 33(2):189-94. PubMed ID: 25452446
[TBL] [Abstract][Full Text] [Related]
10. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma.
Shrubsole MJ; Cai Q; Wen W; Milne G; Smalley WE; Chen Z; Ness RM; Zheng W
Cancer Prev Res (Phila); 2012 Feb; 5(2):336-42. PubMed ID: 22166248
[TBL] [Abstract][Full Text] [Related]
11. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Csiki I; Morrow JD; Sandler A; Shyr Y; Oates J; Williams MK; Dang T; Carbone DP; Johnson DH
Clin Cancer Res; 2005 Sep; 11(18):6634-40. PubMed ID: 16166442
[TBL] [Abstract][Full Text] [Related]
12. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia.
Johnson JC; Schmidt CR; Shrubsole MJ; Billheimer DD; Joshi PR; Morrow JD; Heslin MJ; Washington MK; Ness RM; Zheng W; Schwartz DA; Coffey RJ; Beauchamp RD; Merchant NB
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1358-65. PubMed ID: 16996805
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer.
Morris PG; Zhou XK; Milne GL; Goldstein D; Hawks LC; Dang CT; Modi S; Fornier MN; Hudis CA; Dannenberg AJ
Cancer Prev Res (Phila); 2013 May; 6(5):428-36. PubMed ID: 23531446
[TBL] [Abstract][Full Text] [Related]
14. The volatilome - investigation of volatile organic metabolites (VOM) as potential tumor markers in patients with head and neck squamous cell carcinoma (HNSCC).
Opitz P; Herbarth O
J Otolaryngol Head Neck Surg; 2018 Jul; 47(1):42. PubMed ID: 29970175
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma.
Gallo O; Masini E; Bianchi B; Bruschini L; Paglierani M; Franchi A
Hum Pathol; 2002 Jul; 33(7):708-14. PubMed ID: 12196922
[TBL] [Abstract][Full Text] [Related]
16. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma.
Bergmann C; Strauss L; Zeidler R; Lang S; Whiteside TL
Cancer Res; 2007 Sep; 67(18):8865-73. PubMed ID: 17875728
[TBL] [Abstract][Full Text] [Related]
17. Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs.
Bezawada N; Song M; Wu K; Mehta RS; Milne GL; Ogino S; Fuchs CS; Giovannucci EL; Chan AT
Cancer Prev Res (Phila); 2014 Jul; 7(7):758-65. PubMed ID: 24824037
[TBL] [Abstract][Full Text] [Related]
18. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma.
Cohen EG; Almahmeed T; Du B; Golijanin D; Boyle JO; Soslow RA; Subbaramaiah K; Dannenberg AJ
Clin Cancer Res; 2003 Aug; 9(9):3425-30. PubMed ID: 12960132
[TBL] [Abstract][Full Text] [Related]
19. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.
Khuri FR; Kim ES; Lee JJ; Winn RJ; Benner SE; Lippman SM; Fu KK; Cooper JS; Vokes EE; Chamberlain RM; Williams B; Pajak TF; Goepfert H; Hong WK
Cancer Epidemiol Biomarkers Prev; 2001 Aug; 10(8):823-9. PubMed ID: 11489748
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of 1-hydroxypyrene and N'-nitrosonornicotine in smokers with head and neck cancer: A matched control study.
Khariwala SS; Carmella SG; Stepanov I; Fernandes P; Lassig AA; Yueh B; Hatsukami D; Hecht SS
Head Neck; 2013 Aug; 35(8):1096-100. PubMed ID: 22807150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
